Thymosin alpha 1 and HIV-1: Recent advances and future perspectives

Claudia Matteucci, Sandro Grelli, Emanuela Balestrieri, Antonella Minutolo, Ayele Argaw-Denboba, Beatrice Macchi, Paola Sinibaldi-Vallebona, Carlo Federico Perno, Antonio Mastino, Enrico Garaci

Research output: Contribution to journalReview article

Abstract

In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.

Original languageEnglish
Pages (from-to)141-155
Number of pages15
JournalFuture Microbiology
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

HIV-1
HIV Infections
Immune System
Vaccination
Homeostasis
Therapeutics
Inflammation
T-Lymphocytes
Peptides
Infection
thymalfasin
Neoplasms
Proteins
In Vitro Techniques

Keywords

  • ART
  • CD8 antiviral factor
  • HIV
  • immune dysfunction
  • immune reconstitution

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Matteucci, C., Grelli, S., Balestrieri, E., Minutolo, A., Argaw-Denboba, A., Macchi, B., ... Garaci, E. (2017). Thymosin alpha 1 and HIV-1: Recent advances and future perspectives. Future Microbiology, 12(2), 141-155. https://doi.org/10.2217/fmb-2016-0125

Thymosin alpha 1 and HIV-1 : Recent advances and future perspectives. / Matteucci, Claudia; Grelli, Sandro; Balestrieri, Emanuela; Minutolo, Antonella; Argaw-Denboba, Ayele; Macchi, Beatrice; Sinibaldi-Vallebona, Paola; Perno, Carlo Federico; Mastino, Antonio; Garaci, Enrico.

In: Future Microbiology, Vol. 12, No. 2, 01.02.2017, p. 141-155.

Research output: Contribution to journalReview article

Matteucci, C, Grelli, S, Balestrieri, E, Minutolo, A, Argaw-Denboba, A, Macchi, B, Sinibaldi-Vallebona, P, Perno, CF, Mastino, A & Garaci, E 2017, 'Thymosin alpha 1 and HIV-1: Recent advances and future perspectives', Future Microbiology, vol. 12, no. 2, pp. 141-155. https://doi.org/10.2217/fmb-2016-0125
Matteucci C, Grelli S, Balestrieri E, Minutolo A, Argaw-Denboba A, Macchi B et al. Thymosin alpha 1 and HIV-1: Recent advances and future perspectives. Future Microbiology. 2017 Feb 1;12(2):141-155. https://doi.org/10.2217/fmb-2016-0125
Matteucci, Claudia ; Grelli, Sandro ; Balestrieri, Emanuela ; Minutolo, Antonella ; Argaw-Denboba, Ayele ; Macchi, Beatrice ; Sinibaldi-Vallebona, Paola ; Perno, Carlo Federico ; Mastino, Antonio ; Garaci, Enrico. / Thymosin alpha 1 and HIV-1 : Recent advances and future perspectives. In: Future Microbiology. 2017 ; Vol. 12, No. 2. pp. 141-155.
@article{49a0fe6a65f949e58219370afbb388d7,
title = "Thymosin alpha 1 and HIV-1: Recent advances and future perspectives",
abstract = "In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.",
keywords = "ART, CD8 antiviral factor, HIV, immune dysfunction, immune reconstitution",
author = "Claudia Matteucci and Sandro Grelli and Emanuela Balestrieri and Antonella Minutolo and Ayele Argaw-Denboba and Beatrice Macchi and Paola Sinibaldi-Vallebona and Perno, {Carlo Federico} and Antonio Mastino and Enrico Garaci",
year = "2017",
month = "2",
day = "1",
doi = "10.2217/fmb-2016-0125",
language = "English",
volume = "12",
pages = "141--155",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Thymosin alpha 1 and HIV-1

T2 - Recent advances and future perspectives

AU - Matteucci, Claudia

AU - Grelli, Sandro

AU - Balestrieri, Emanuela

AU - Minutolo, Antonella

AU - Argaw-Denboba, Ayele

AU - Macchi, Beatrice

AU - Sinibaldi-Vallebona, Paola

AU - Perno, Carlo Federico

AU - Mastino, Antonio

AU - Garaci, Enrico

PY - 2017/2/1

Y1 - 2017/2/1

N2 - In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.

AB - In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.

KW - ART

KW - CD8 antiviral factor

KW - HIV

KW - immune dysfunction

KW - immune reconstitution

UR - http://www.scopus.com/inward/record.url?scp=85011263052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011263052&partnerID=8YFLogxK

U2 - 10.2217/fmb-2016-0125

DO - 10.2217/fmb-2016-0125

M3 - Review article

AN - SCOPUS:85011263052

VL - 12

SP - 141

EP - 155

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 2

ER -